Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 9/2002

01.08.2002 | Original Research Article

Cost Effectiveness of Treatment of Parkinson’s Disease with Entacapone in the United States

verfasst von: Cynthia S. Palmer, Dr Mark J.C. Nuijten, Jordana K. Schmier, Prasun Subedi, Edward H. Snyder

Erschienen in: PharmacoEconomics | Ausgabe 9/2002

Einloggen, um Zugang zu erhalten

Abstract

Objective: To determine the cost effectiveness of adjunctive therapy with entacapone versus standard treatment (levodopa) without entacapone for patients in the US with Parkinson’s disease (PD)who experience ‘off-time’ (re-emergence of the symptoms of PD) while receiving levodopa.
Study Design: A Markov model was used to estimate 5-year costs and effectiveness of standard treatment with and without entacapone.
Methods: Probabilities, unit costs, resource utilisation data and utilities were obtained from published literature, clinical trial reports, a national database, and clinical experts. PD disability was measured using the daily proportion of off-time and Hoehn and Yahr scale scores. The analysis measured costs from a societal and third-party payer perspective, and effectiveness as gains in quality-adjusted life-years (QALYs) and years without progression to >25% off-time.
Results: From a societal perspective, entacapone therapy resulted in an incremental cost of $US9327 per QALY gained compared with standard treatment. Treatment with entacapone also provided an additional 7.6 months with ≤25% off-time/day compared with standard treatment. Sensitivity analyses indicated that the model is sensitive to changes in rates of improvement/deterioration of off-time, and to the number of doses per day of levodopa with adjunctive entacapone.
Conclusions: The addition of entacapone to standard treatment for patients receiving levodopa who experience off-time provides additional QALYs and gain in time with minimal fluctuations. Results of this modelling exercise suggest that therapy with entacapone may be cost effective when compared with standard treatment for PD.
Fußnoten
1
The ‘pull test’ is a standard component of assessment of postural stability in Parkinson’s disease. It evaluates the response to sudden, strong posterior displacement produced by pulling on the shoulders while the patient is erect with eyes open and feet slightly apart. The patient is prepared.
 
Literatur
1.
Koller WC. Classification of parkinsonism. In: Koller WC, editor. Handbook of Parkinson’s disease. New York (NY): Marcel Dekker, Inc., 1987: 51–80
2.
de Pedro-Cuesta J, Stawiarz L. Parkinson’s disease incidence: magnitude, comparability, time trends. Acta Neurol Scand 1991; 84: 382–8PubMedCrossRef
3.
Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin 1992; 10: 317–29PubMed
4.
Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, et al., editors. Neurologic disorders: course and treatment. San Diego (CA): Academic Press, 1996: 715–72
5.
Rajput AH, Offord KP, Beard CM, et al. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 1987; 37: 226–32PubMedCrossRef
6.
Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann Neurol 1998; 43: 318–25CrossRef
7.
Yahr MD. Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, editors. Advances in parkinsonism. Basel: Editiones Roche, 1976: 435–43
8.
Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1993; Suppl. 19: 253–64
9.
Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmstead County project. Neurology 1993; 43: 1918–26PubMedCrossRef
10.
Bonnet AM, Marconi R, Vidailhe M, et al. Levodopa versus bromocriptine-induced dyskinesia in Parkinson’s disease. New Trends Clin Neuropharmacol 1992; 6: 1–4
11.
Marconi R, Lefebvre-Caparros D, Bonnet A, et al. Levodopa induced dyskinesias in Parkinson’s disease. Phenomenology and pathophysiology. Mov Disord 1994; 1: 2–12CrossRef
12.
Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000; 57: 953–61PubMed
13.
Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299–312PubMedCrossRef
14.
Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421–8PubMedCrossRef
15.
Rinne UK. Problems associated with long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 1983; 95: 19–26CrossRef
16.
Djaldetti R, Melamed E. Management of response fluctuations: practical guidelines. Neurology 1998; 51 Suppl. 2: S36-40PubMedCrossRef
17.
Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson’s disease. Mov Disord 1998; 13: 406–13PubMedCrossRef
18.
Clarke CE, Zobkiw RM, Gullaksen E. Quality of life and care in Parkinson’s disease. Br J Clin Pract 1995; 49: 288–93PubMed
19.
Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial. Am J Med 1994; 97: 429–35PubMedCrossRef
20.
Mercer BS. A randomized study of the efficacy of the PROPATH program for patients with Parkinson disease. Arch Neurol 1996; 53: 881–4PubMedCrossRef
21.
Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844–9PubMed
22.
Dodel RC, Pepperl S, Köhne-Volland R, et al. Medizinische ökonomie: kosten der medikamentösen behandlung neurologischer erkrankungen: morbus parkinson, dystonie, epilepsie. Med Klin 1996; 91: 483–5
23.
Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson’s disease. Mov Disord 1998; 13: 249–54PubMedCrossRef
24.
Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson’s disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure survey. Pharmacoeconomics 1997; 12: 486–98PubMedCrossRef
25.
Le Pen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999; 16: 59–69CrossRef
26.
Hempel AG, Wagner ML, Maaty MA, et al. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998; 32: 878–83PubMedCrossRef
27.
Hoerger TJ, Bala MV, Rowland C, et al. Cost-effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics 1998; 14: 541–57PubMedCrossRef
28.
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997; 42: 747–55CrossRef
29.
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309–14PubMedCrossRef
30.
PhRMA Task Force on the Economic Evaluation of Pharmaceuticals. Methodological and Conduct Principles for Pharmacoeconomic Research. Washington (DC): Pharmaceutical Research and Manufacturers of America, 1995
31.
Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
32.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–42PubMedCrossRef
33.
Decision analysis by Tree Age (DATA) Software, Version 3.14 for Windows [computer program]. Williamstown (MA): TreeAge Software, Inc., 1996
34.
Beck JR, Pauker SG. The Markov process in medical diagnosis. Med Decis Making 1983; 3: 419–58PubMedCrossRef
35.
Barr JT, Schumacher GE. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven; 1996: 1197–214
36.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38PubMedCrossRef
37.
Palmer CS, Schmier J, Snyder E, et al. Patient preferences and utilities for “off-time” outcomes in the treatment of Parkinson’s disease. Qual Life Res 2000; 9 (7): 819–27PubMedCrossRef
38.
Schlenker RE, Kramer AM, Hrincevich CA, et al. Rehabilitation costs: implications for prospective payment. Health Serv Res 1997; 32: 651–68PubMed
39.
Health Care Consultants of America. 1999 physicians fee and coding guide. Augusta (GA): HealthCare Consultants of America, 1999
40.
National Association of Psychiatric Health Systems. Trends in psychiatric health systems. 1995 annual survey: final report. Washington (DC): National Association of Psychiatric Health Systems, 1995: 13
41.
MEDTAP database of international unit costs. Berthesda (MD): Medtap International, 2001
42.
Medical Economics Company. 1999 red book. Montvale (NJ): Medical Economics Company, 1999
43.
Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 202–3
44.
Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982; 73: 889–97PubMedCrossRef
45.
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization?. Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473–81PubMed
46.
Nuijten MJC. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998; 13 (3): 305–16PubMedCrossRef
47.
Nuijten MJC. Bridging decision analytic modelling with a cross-sectional approach. PharmacoEconomics 2000 Mar; 17 (3): 227–36
48.
Olanow CW, Shapira AHV, Rascol O. Continuous dopamine stimulation in early Parkinson’s disease. Trends Neurosci 2000; 23: S117–26PubMedCrossRef
49.
Kieburtz K, Hubble J. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials. Neurology 2000; 55 (11 Suppl. 4): S42–5PubMed
50.
Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5 (3): 249–68PubMedCrossRef
Metadaten
Titel
Cost Effectiveness of Treatment of Parkinson’s Disease with Entacapone in the United States
verfasst von
Cynthia S. Palmer
Dr Mark J.C. Nuijten
Jordana K. Schmier
Prasun Subedi
Edward H. Snyder
Publikationsdatum
01.08.2002
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2002
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220090-00005

Weitere Artikel der Ausgabe 9/2002

PharmacoEconomics 9/2002 Zur Ausgabe

Original Research Article

Assessment of Health Economics in Alzheimer’s Disease (AHEAD)

Original Research Article

Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications

Review Article

On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease

Original Research Article

Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis

Review Article

Reference-Based Pricing Schemes